Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cancer Research

• Publication date

  2006-10-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-06-1684PMID 17047074
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.

  2005cited by this paper
• Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells.

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.

  2005cited by this paper
• Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.

  2005cited by this paper
• Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

  2004cited by this paper
• Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255

  2004cited by this paper
• The ErbB/HER receptor protein-tyrosine kinases and cancer*1

  2004cited by this paper
• Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer

  2004cited by this paper
• Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.

  2004cited by this paper
• The ErbB/HER receptor protein-tyrosine kinases and cancer.

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• The Mitogenic Action of Insulin-like Growth Factor I in Normal Human Mammary Epithelial Cells Requires the Epidermal Growth Factor Receptor Tyrosine Kinase*

  2004cited by this paper
• Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor I-induced activation of extracellular signal-regulated kinase in oral carcinoma cells.

  2004cited by this paper
• Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.

  2004cited by this paper
• Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

  2004cited by this paper
• Epidermal growth factor receptor as a target in cancer therapy.

  2003cited by this paper
• Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells.

  2003cited by this paper
• Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.

  2003cited by this paper
• Erlotinib: preclinical investigations.

  2003cited by this paper
• Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer

  2003cited by this paper
• Cancer Statistics, 2003

  2003cited by this paper
• Survivin and apoptosis control.

  2003cited by this paper
• Rituximab in chronic lymphocytic leukemia.

  2003cited by this paper
• Erlotinib (Tarceva): an update on the clinical trial program.

  2003cited by this paper
• Novel approaches to the treatment of non-small cell lung cancer.

  2002cited by this paper
• Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants

  2002cited by this paper
• Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.

  2002influential reference
• Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor Receptor*

  2002cited by this paper
• Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission

  2001cited by this paper
• The epidermal growth factor receptor as a target for cancer therapy.

  2001cited by this paper
• XIAP: Apoptotic brake and promising therapeutic target

  2001cited by this paper
• New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades

  2001cited by this paper
• G-protein-coupled receptors and signaling networks: emerging paradigms.

  2001cited by this paper
• Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells

  2001cited by this paper
• Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association.

  2001cited by this paper
• Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

  2001cited by this paper
• Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.

  2001cited by this paper
• Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody

  2001cited by this paper
• Transactivation of the EGF Receptor Mediates IGF-1-stimulated Shc Phosphorylation and ERK1/2 Activation in COS-7 Cells*

  2000cited by this paper
• Insulin-like growth factor physiology and cancer risk.

  2000cited by this paper
• Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein.

  1999cited by this paper
• Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism.

  1999cited by this paper
• Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.

  1999cited by this paper
• Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor

  1998cited by this paper
• Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

  1997cited by this paper
• Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins.

  1997cited by this paper
• EGF receptor in neoplasia and metastasis

  1993cited by this paper
• Insulin-like growth factor-I receptors in human glial tumors.

  1990cited by this paper
• Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen.

  1989cited by this paper

• Top 100 most-cited articles on apoptosis of non-small cell lung cancer over the past two decades: a bibliometrics analysis

  2025cites this paper
• EGFR mutations in non-small cell lung cancer: Classification, characteristics and resistance to third-generation EGFR-tyrosine kinase inhibitors (Review)

  2025cites this paper
• The signaling landscape of insulin-like growth factor 1

  2024cites this paper
• Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment

  2024cites this paper
• The Relationship between IGF Pathway and Acquired Resistance to Tyrosine Kinase Inhibitors in Cancer Therapy.

  2023cites this paper
• The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies

  2023cites this paper
• Role of YES1 signaling in tumor therapy resistance

  2023cites this paper
• Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor

  2023cites this paper
• Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer.

  2023cites this paper
• Second-Generation JK-206 Targets the Oncogenic Signal Mediator RHOA in Gastric Cancer

  2022cites this paper
• Computational Methods for the Analysis and Prediction of EGFR-Mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects

  2022cites this paper
• The Therapeutic Landscape of Salivary Gland Malignancies—Where Are We Now?

  2022cites this paper
• Heterogeneity of glutamine metabolism in acquired-EGFR-TKI-resistant lung cancer.

  2022cites this paper
• MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells

  2022cites this paper
• Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.

  2021cites this paper
• Genotype-determined EGFR-RTK heterodimerization and its effects on drug resistance in lung Cancer treatment revealed by molecular dynamics simulations

  2021cites this paper
• Computational methods for the analysis and prediction of drug resistance in EGFR-mutated non-small cell lung cancer patients

  2021cites this paper
• Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance

  2021cites this paper
• Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

  2021cites this paper
• Design, synthesis and biological evaluation of 2,3-dihydroimidazo[2,1-b]thiazoles as dual EGFR and IGF1R inhibitors.

  2021cites this paper
• Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy

  2021cites this paper
• Investigation of serum survivin in dogs suffering from cancer: a multicenter study

  2021cites this paper
• Lurasidone Sensitizes Cancer Cells to Osimertinib by Inducing Autophagy and Reduction of Survivin

  2021cites this paper
• Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer

  2020cites this paper
• New Insights from IGF-IR Stimulating Activity Analyses: Pathological Considerations †

  2020cites this paper
• Hitting the right targets : a study of molecular mediators of sensitivity to novel potential targeted therapies in cutaneous malignant melanoma

  2020cites this paper
• ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications

  2020cites this paper
• Relationships between DNA repair and RTK-mediated signaling pathways.

  2020cites this paper
• B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine

  2020cites this paper
• Immunohistochemical expression of insulin-like growth factor-1Ec in primary endometrial carcinoma: Association with PTEN, p53 and survivin expression

  2020cites this paper
• Survivin silencing improved the cytotoxicity of carboplatin and melphalan in Y79 and primary retinoblastoma cells.

  2020cites this paper
• Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer

  2020cites this paper
• Effects of insulin on IGF-1 receptors in equine lamellar tissue in vitro.

  2020cites this paper
• Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer

  2020cites this paper
• Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer

  2020cites this paper
• Restoring apoptosis dysregulation using survivin inhibitor in nasopharyngeal cancer

  2020cites this paper
• Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery

  2020cites this paper
• Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs

  2019cites this paper
• FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective.

  2019cites this paper
• Prognosis related miRNAs, DNA methylation, and epigenetic interactions in lung adenocarcinoma.

  2019cites this paper
• Insulin-like growth factor (IGF) signaling in T-cell acute lymphoblastic leukemia.

  2019cites this paper
• FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy

  2019cites this paper
• Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction

  2019cites this paper
• Survivin in Insulin-Like Growth Factor-Induced Resistance to Lapatinib in Head and Neck Squamous Carcinoma Cells

  2019cites this paper
• Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer

  2019cites this paper
• Dual Targeting of EGFR and IGF1R in the TNFAIP8 Knockdown Non–Small Cell Lung Cancer Cells

  2019cites this paper
• Inhibition of EGFR attenuates fibrosis and stellate cell activation in diet-induced model of nonalcoholic fatty liver disease.

  2018cites this paper
• Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

  2018cites this paper
• Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

  2018cites this paper
• GATA3 as a master regulator and therapeutic target in ovarian high‐grade serous carcinoma stem cells

  2018cites this paper
• Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib

  2018cites this paper
• Molecular Signatures of the Insulin-Like Growth Factor 1-Mediated Epithelial-Mesenchymal Transition in Breast, Lung and Gastric Cancers

  2018cites this paper
• EGFR signaling from the early endosome.

  2018cites this paper
• Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage

  2018cites this paper
• The RTK Interactome: Overview and Perspective on RTK Heterointeractions.

  2018cites this paper
• A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.

  2018cites this paper
• Comparative mRNA and miRNA transcriptome analysis of a mouse model of IGFIR-driven lung cancer

  2018cites this paper
• Suppressor of cytokine signalling-2 limits IGF1R-mediated regulation of epithelial–mesenchymal transition in lung adenocarcinoma

  2018cites this paper
• Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer

  2018cites this paper
• Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway

  2018cites this paper
• Pan-HER-targeted approach for cancer therapy: Mechanisms, recent advances and clinical prospect.

  2018cites this paper
• Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives.

  2018cites this paper
• Understanding and targeting resistance mechanisms in NSCLC

  2017cites this paper
• Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

  2017cites this paper
• Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies

  2017cites this paper
• IGF system targeted therapy: Therapeutic opportunities for ovarian cancer.

  2017cites this paper
• 6.01 – Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R

  2017cites this paper
• Determinación del papel de FGFR1 y FGFR4 en cáncer de pulmón.

  2017cites this paper
• Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI‐906) or Placebo in Chemotherapy‐Naive Patients With Non–Small‐Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

  2017cites this paper
• Simultaneous inhibition of IGF1R and EGFR enhances the efficacy of standard treatment for colorectal cancer by the impairment of DNA repair and the induction of cell death.

  2017cites this paper
• Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC

  2017cites this paper
• Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R

  2017cites this paper
• Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy

  2017cites this paper
• Dexamethasone-( c 21-phosphoramide )-[ anti-egFr ] : molecular design , synthetic organic chemistry reactions , and antineoplastic cytotoxic potency against pulmonary adenocarcinoma ( a 549 )

  2016cites this paper
• Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells

  2016cites this paper
• A monoclonal antibody targeting the dimer interface of epidermal growth factor receptor (EGFR).

  2016cites this paper
• EGR 1 , EGFR and IGF 1 R protein expressions in non-small cell lung cancer and their clinical significances

  2016cites this paper
• Mechanisms of resistance to EGFR-targeted drugs: lung cancer

  2016cites this paper
• Type I insulin-like growth factor receptor signaling in hematological malignancies

  2016influential citation
• Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer

  2016cites this paper
• - Computational Characterization of Non-small-cell Lung Cancer with EGFR Gene Mutations and its Applications to Drug Resistance Prediction

  2016cites this paper
• The growing story of (ARABIDOPSIS) CRINKLY 4.

  2016cites this paper
• Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?

  2016cites this paper
• ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma

  2016cites this paper
• BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma

  2016cites this paper
• Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab

  2016cites this paper
• Characterization of select downstream effectors of oncogenic NOTCH1 in T-cell acute lymphoblastic leukemia

  2016cites this paper
• MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines

  2016cites this paper
• Combination therapy approaches to target insulin-like growth factor receptor signaling in breast cancer.

  2016cites this paper
• Isolation of EGFR-containing early endosomes.

  2016cites this paper
• The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma

  2016cites this paper
• A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors

  2016cites this paper
• Targeting the Mammalian Target of Rapamycin in Lung Cancer☆

  2016cites this paper
• Discovery of dually acting small-molecule inhibitors of cancer-resistance relevant receptor tyrosine kinases EGFR and IGF-1R

  2016cites this paper
• Resistance to Therapy.

  2016cites this paper
• Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer

  2016cites this paper
• Antiproliferative effects of γ-tocotrienol are associated with lipid raft disruption in HER2-positive human breast cancer cells.

  2016cites this paper
• Essential Role of DNA Methyltransferase 1–mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors

  2016cites this paper
• Association between survivin genetic polymorphisms and epidermal growth factor receptor mutation in non-small-cell lung cancer

  2016cites this paper
• Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)

  2016cites this paper